drugset / Trial / NCT01445028
Isotretinoin for Proliferative Vitreoretinopathy
Non-randomizedParallel-groupOpen-labelPrevention
Summary
Proliferative vitreoretinopathy (PVR), or secondary scarring on and around the retina, is an important cause of retinal re-detachment. The purpose of this study is to evaluate the effect of oral isotretinoin, which inhibits the growth of cells responsible for proliferative vitreoretinopathy (PVR), on recurrent retinal detachment.
Timeline
- Start
- 2011-09
- Primary completion
- 2013-08
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Isotretinoin | Other / unclassified | 20 mg | Oral |